Akero Therapeutics Inc.

Akero Therapeutics Inc. concentrates its research efforts on addressing complex liver conditions associated with metabolic dysfunction. The organisation investigates therapeutic interventions targeting non-alcoholic steatohepatitis (NASH), a progressive form of fatty liver disease characterised by hepatic inflammation and cellular damage. Their clinical programmes examine the pathophysiology of metabolic dysfunction-associated steatohepatitis (MASH), focusing on the interplay between hepatic lipid accumulation, inflammatory processes, and fibrotic tissue development.

• Non-Alcoholic Steatohepatitis and Liver Fibrosis
• Metabolic Dysfunction-Associated Steatohepatitis
• Hepatic Lipotoxicity and Inflammation

The sponsor's research portfolio emphasises the development of novel pharmacological approaches to halt or reverse liver fibrosis progression in patients with metabolically driven hepatic disease. Their investigations explore mechanisms that address both the metabolic and inflammatory components underlying chronic liver injury.